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Abstract
Objectives: The aim of this study was to compare
aspects of the quality of life of drug users on a methadone
maintenance programme to drug users on a harm
minimisation programme. 
Method: Thirty-six clients attending the harm
minimisation programme in the National Drug Treatment
Centre, Dublin, were matched for age and sex to 36 clients
on the methadone maintenance programme. All were
interviewed with the SF-36 Health Survey Questionnaire
to measure health related quality of life and with the
Hospital Anxiety and Depression Scale (HADs) to measure
psychological morbidity. 
Results: More clients from the harm minimisation
programme had previous psychiatric problems than clients
on the methadone maintenance programme, with an odds
ratio of 4.3 CI(1.2,15.2). On the HADs, clients on the
methadone maintenance programme had significantly
lower depression scores than clients on the harm
minimisation programme. In addition more clients on the
harm minimisation programme were severely depressed
than clients on the methadone maintenance programme.
On the UK SF-36 Scale, clients on the harm minimisation
programme perceived a significantly greater deterioration
in ‘change in health’ over the previous year than clients on
the methadone maintenance programme.
Conclusions: Although clients on a methadone
maintenance programme had an improved perception of
their quality of life in relation to psychological and overall
health function from the previous year, compared to clients
on a harm minimisation programme, there still existed
varying degrees of psychopathology in both groups which
need to be considered when providing future services for
drug users.
Key words: Quality of life; Methadone maintenance
programme; Harm minimisation programme.
Introduction
Health, as defined by the World Health Organisation, is
‘a state of complete physical, mental and social well-being
and not merely the absence of disease or infirmity’.1
Patients’ perceptions of their level of functioning in these
areas provides a basis for estimating their perceived qual-
ity of life. Of particular influence in defining and
measuring components of ‘quality of life’ was the work
carried out by the Rand Corporation in the Health Insur-
ance experiment and later in the Medical Outcomes
Study.2,3 They developed a self report questionnaire, the
Short Form 36 (SF-36) to measure health status and qual-
ity of life. 
Although there has been much interest in assessing the
quality of life of patients with specific illnesses and
diseases, there have been few studies that assess the quality
of life of opiate drug users. Torrens et al in a prospective
three year study found, through the use of the Nottingham
Health Profile, that opioid users, when treated with a
methadone maintenance programme for a 12 month
period, experienced an early and substantial improvement
in health related quality of life.4 The most significant
improvements were within the first to third month of treat-
ment. The authors suggested that measuring changes in the
health related quality of life can constitute a measurement
of treatment effectiveness and can be used to evaluate drug
treatment programmes. Ryan et al assessed health status at
entry to a methadone maintenance treatment using the SF-
36 health survey questionnaire and found that scores for
heroin users were significantly worse for physical and
psychological health than for the general population.5
Scores for psychological functioning were most similar to
clinically depressed patients while self-perceived general
health was equivalent to patients who had a severe medical
illness. 
Marsden et al explored the prevalence of psychiatric
symptoms amongst clients seeking treatment for drug
dependency based on data obtained from the National
Treatment Outcome Research Study.6 They found a ‘condi-
tional’ relationship between psychiatric symptoms and
substance use. For primary opiate drug users without poly-
drug use, their drug intake did not correlate with
psychiatric symptoms. However, when opiate use is asso-
ciated with polydrug use with stimulants and
benzodiazepines or alcohol use, then the severity of drug
use was found to be related to psychiatric symptoms.
The Epidemiologic Catchment Area study showed that
53% of drug users had a mental disorder, with anxiety
disorders being the most common diagnosis, accounting
for 28% of psychiatric conditions, followed by affective
disorders at 26%.7 Rounsaville et al found that 70% of
drug users had an associated psychiatric diagnosis to drug
dependency. Elevated scores for measures of depression,
anxiety and antisocial personality were common in heroin
using populations.8 In an Irish population of drug users on
methadone maintenance, 83% exhibited some level of
depression, 27% scored in the moderately depressed range
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and 56% scored in the severely depressed range of the
Beck Depression Inventory.9
The aim of this study was to assess the perceived quality
of life and psychological morbidity of clients on a harm
minimisation programme and to compare results to clients
attending a methadone maintenance drug treatment
programme. 
Method
All clients attending a harm minimisation programme in
the National Drug Treatment Centre, Dublin, were
requested to take part in the study. The programme
consisted of a needle exchange programme, 20mg of
methadone daily, and access to medical personnel. These
clients were matched for age and sex to clients attending a
methadone maintenance programme and written consent
was obtained from all who took part in the study. Data
regarding the demographic characteristics of both groups
and the amount, duration and frequency of present and
past drug use was collected. Information was obtained
from clients about past psychiatric histories and about a
range of subjective psychological experiences that they had
had in the past and specifically in the previous 30 days.
These included whether they had experienced depression,
anxiety, difficulties in concentration, visual hallucinations,
suicidal ideation or had engaged in a suicidal attempt.
Specific scales were used in the study to measure psycho-
logical, physical and social function.
Scales used
The SF-36 general health questionnaire is a generic
measure of health status and quality of life. It is a 36 item
questionnaire which evaluates individuals’ perceptions of
their performance in eight dimensions of daily life, corre-
sponding to three aspects of health, ie. functional status,
well-being and ‘overall evaluation of health’. The four
scales measuring functional status are physical functioning
(10 items), role limitations due to physical problems (four
items), role limitations due to emotional problems (three
items) and social functioning (two items). 
‘Wellbeing’ has three scales: mental health (five items),
energy/vitality (four items) and bodily pain (two items).
The overall evaluation of health is obtained from a
person’s perception of their general health (five items).
There is a further unscaled single item asking respondents
about health change over the past year. For each variable,
item scores are summed and transformed to give eight
scores with a 0-100 scale. Higher scores indicate better
function. The SF-36 has a US and a UK version and has
been shown to be a valid and reliable instrument for
measuring overall health status.10-12 Recently, normative
values for an Irish population have been presented and the
US version of the SF-36 was found to have acceptable
consistency and  validity.13 Permission for use of the UK
version of the SF-36 was obtained for this study.14
The Hospital Anxiety and Depression Scale measures
states of anxiety and depression. This is a self-assessment
scale which has been found to be a reliable instrument for
detecting states and severity of depression and anxiety in
the setting of a hospital medical outpatient clinic. A score
of 0-7 is interpreted as ‘normal’, 8-10 as ‘mild’, 11-14 as
‘moderate’ and 15-21 as ‘severe’ levels of anxiety or
depression.15
Statistical analysis
The unit of analysis was the matched pair and there
were 36 pairs, each consisting of a client from the harm
minimisation programme and a client matched for age and
sex from the methadone maintenance programme. The
differences in the two programmes were compared and
subjected to appropriate tests of statistical analysis. For
categorical variables with two categories the results were
assessed using McNemar’s test. The results of the test, the
odds ratio (OR) and associated 95% confidence interval
are reported. For some variables the estimated OR is infi-
nite (OR infinite). This happens when there are no
case/control pairs in which the control had been exposed
to the risk factor and the case had not. In such cases, we
have simply noted that the OR could not be reliably esti-
mated. For categorical variables with more than two
categories an extension of McNemar’s test – a symmetry
test was used.16 If in addition the categories were ordered
then a conditional symmetry test was used. For continu-
ous variables comparisons were made using the Wilcoxon
signed rank test. 
Results
There were 25(69%) males from each programme and
the average age was 32 years. There was no difference in
marital status between the two groups. Significantly more
clients on the methadone maintenance programme were
living in their own accommodation while more on the
harm minimisation programme were living in the family
home (symmetry test p = 0.001). Significantly more clients
on the methadone maintenance programme were
employed (McNemar’s test p = 0.05, OR 4.5 CI(1.0,14.6)).
There were no significant differences between the two
Table 1: Demographic characteristics
Methadone Harm
maintenance minimisation
programme programme
Sex M : F 25 (69%) : 11 (31%) 25 (69%) : 11 (31%)
Marital Status
Single 23 (63.9%) 18 (50%)
Married/co-habiting 11 (30.5%) 13 (36.1%)
Separated/divorced 2 (5.6%) 4 (11.1%)
Widowed 0% 1 (2.8%)
*Accommodation
Home 1 (2.8%) 14 (38.9%)
Own house/flat 11 (30.5%) 0 (0%)
Rented 23 (63.9%) 17 (47.2%)
Hostel 1 (2.8%) 5 (13.9%)
*Employment 10 (27.8%) 3 (8.3%)
Level of Education
Primary 8 (22%) 13 (36%)
Secondary 28( 78%) 19 (53%)
Higher Education 0 (0%) 4 (11%)
*p < 0.05
5. drug users/Rooney5  27/5/02 2:28 PM  Page 2
Ir J Psych Med 2002; 19(2): 55-59
57
groups in terms of highest level of education obtained (see
Table 1).
History of drug use
There was no difference between the two groups with
regard to age of first use of specific drugs and alcohol. The
main difference between the two groups was that cocaine
was used significantly longer by clients on the harm
minimisation programme, while use of analgesics was
more common in the methadone maintenance programme.
Cocaine was used for 4.4 years longer by clients on the
harm minimisation programme compared to clients on the
methadone maintenance programme, p = 0.05. Signifi-
cantly more on the methadone maintenance programme
used analgesics, (p = 0.001, OR 10.5, CI(2.5,44.8)). 
There was a trend for the methadone maintenance
clients to have used alcohol longer than the harm minimi-
sation clients, the difference being 2.06 years, p = 0.07.
Significantly more in the harm minimisation programme
had used heroin (p = 0.002, OR 24, CI(3.2,177.4)) and
benzodiazepines (p = 0.000, OR infinite – see explanation
in the methods section) in the previous 30 days prior to the
interview. Significantly more clients on the harm minimi-
sation programme had injected in general, (p = 0.000, OR
infinite), had injected within the last six months (p =
0.002, OR 6.7, CI(2.0,22.4)) and within the previous 30
days, (p = 0.000, OR infinite). There were no significant
differences in the numbers who shared needles in both
groups. Clients from both groups had a mean age of first
injecting at 21 years.
Clients on the harm minimisation programme had had
more past treatments for drug misuse, an average of 2.7
times more compared to clients on the methadone mainte-
nance programme, (p = 0.06). In particular, they had
significantly more outpatient methadone stabilisation
programmes, (p = 0.02, OR 4.3, CI(1.2,15.2). 
Clients on the harm minimisation programme spent on
average per month £1,200 (e1,524) on drugs compared to
£16 (e20) for clients on the methadone maintenance
programme, p = 0.0001. The amounts ranged from £0-
£10,000 (e1,2697) per month. 
Psychological health
A total of 22(61%) on the harm minimisation
programme and 15(41.7%) on the methadone mainte-
nance programme stated they had had previous
psychological or emotional problems. More clients on the
harm minimisation programme stated they had a previous
psychiatric history, (p = 0.02, OR 4.3 CI(1.2,15.2)). There
were no differences between the two groups in the number
of past admissions to a psychiatric unit, but significantly
more in the harm minimisation programme had attended
and received treatment in a psychiatric outpatients depart-
ment, (p = 0.01, OR 12.0, CI(1.6,92.3)). 
Significantly more in the harm minimisation programme
reported suffering with depression (p = 0.007, OR 7.5,
CI(1.7,32.8)) and specifically within the previous 30 days
(p = 0.03, OR 3.0, CI(1.1,8.3)). Evidence of greater levels
of drug intoxication experienced by the harm minimisation
group is indicated by significantly more reporting difficulty
in understanding, concentrating and remembering in
general (p = 0.01, OR 5, CI(1.4,17.3)), but specifically in
the past 30 days (p = 0.01, OR 4.7, CI(1.3,16.2)) and
significantly more having experienced visual hallucinations
(p = 0.000, OR infinite). This group reported significantly
more suicidal ideation (p = 0.03, OR 3, CI(1.1,8.3)) but
there were no significant differences between the two
groups in the number of parasuicide attempts, (mean
number was one). There were no differences in the subjec-
tive experience of anxiety reported by the two groups.
On the HADs, both groups showed various degrees of
anxiety, but there were no significant differences in the
scores between the two groups. However, in a comparison
of the depression scores from the HADs, the mean score
for clients on the harm minimisation programme was 10.8,
significantly higher than the mean score of 6.4 (p =
0.00003) for clients on the methadone maintenance
programme. In addition, the harm minimisation
programme had significantly more clients registering a
score for severe depression, (p = 0.03, OR 5.5, CI
(1.2,24.8)). Twenty-four clients (66.7%) on the harm
minimisation programme registered some level of depres-
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Anxiety Depression
Methadone
maintenance
programme
Methadone
maintenance
programme
Harm
minimisation
programme
Harm
minimisation
programme
Figure 1: Differences in scores between the two groups on the Hospital Anxiety and Depression Scale
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sion with 11(31%) severely depressed. Eleven clients
(31%) on the methadone maintenance programme had
some level of depression and 2(5.1%) were severely
depressed, (see Figure 1).
With regard to analysis of the UK SF-36 Scale, no differ-
ences were found in the scores between the two groups in
the dimensions of physical functioning, role limitation due
to physical or emotional problems, social functioning,
mental health, energy and vitality, bodily pain and general
health perception. Perceived ‘change in health’ from the
previous year showed a large difference indicating a
greater perceived deterioration of health for clients on the
harm minimisation programme and a perceived improve-
ment in health from the previous year for clients on the
methadone maintenance programme (p = 0.003). 
Discussion
This study has methodological limitations as it offers
only a snap-shot comparison of two service modalities
rather than a prospective analysis over time between the
two treatment programmes. Although the SF-36 has been
found to be a reliable and valid instrument for measuring
the quality of life in the US, UK and more recently in
Ireland, it is not known if it is transferable to an Irish
population of drug users. Irish drug users may have a
different perception of quality of life which may be very
culturally specific. The other limitation of this study is the
selection of patients. A harm minimisation programme by
its nature will have more chaotic clients and therefore the
differences noted between the two programmes are not a
measure of treatment effectiveness but of client selection,
and as such, the findings need to be considered in light of
these limitations.
Attenders on the harm minimisation programme were
less self sufficient than clients on the methadone mainte-
nance programme as indicated by a greater dependence on
families for accommodation and a lower employment rate.
They had a more severe pattern of drug use as evidenced
by a larger current use of a number of drugs such as
heroin, benzodiazepines and cocaine, symptoms of drug
intoxication, more past treatments for drug dependency
and a higher monthly expenditure on drugs. They were
engaged in more risk behaviour as indicated by a greater
intravenous use of drugs, both in the past and currently
(see Table 2). 
Clients on the harm minimisation programme had used
cocaine significantly longer than clients on the methadone
maintenance programme. This drug has mood alleviating
properties and the longer use may be an attempt to self
medicate and relieve depressive symptoms that can arise
secondary to drug misuse. Alternatively, a greater vulnera-
bility to suffering depressive symptoms may have been a
primary contributing factor to taking drugs initially. Schot-
tenfeld, in a review, summarised how cocaine users had a
high rate of psychopathology for anxiety and affective
disorders, attention deficit disorders and personality disor-
ders.17
The methadone maintenance group had a higher rate of
use of alcohol and analgesics. Ryan et al found that a
greater use of alcohol in heroin users at entry to a
methadone maintenance programme was associated with
higher physical functioning and vitality but poorer social
functioning.5 The reasons for the greater use of analgesics
by this group is unclear, but it may be related to the degree
of heroin dependency and an attempt to self medicate to
treat opioid withdrawal symptoms. The use of analgesics
may also identify a group of drug users who are more
likely to seek treatment for their drug use because of the
experience of distressing withdrawal symptoms in contrast
to drug users who have adjusted to their life-style whereby
physical symptoms are no longer intrusive.
Both groups differed in terms of degree of psychological
symptoms. More clients on the harm minimisation
programme had past psychological problems or psychi-
atric history with more having attended psychiatric
outpatient services. More reported experiencing depression
and suicidal ideation in their lives. This was confirmed by
scores on the Hospital Anxiety and Depression Scale
whereby, clients on the harm minimisation programme
were more severely depressed than clients on the
methadone maintenance programme. These results indi-
cate a high level of psychological morbidity and suicidal
risk in a group of drug users not in treatment. Although
clients on the methadone maintenance programme had
lower levels of depression, psychopathology still existed as
31% were depressed and 39% had had a previous suicidal
attempt despite being in treatment. The evidence of
psychopathology in drug users on methadone maintenance
has been outlined in previous studies9,18,19 and how a fail-
ure to address psychiatric co-morbidity and substance
misuse can lead to poorer treatment outcomes.20
Although no significant differences were found between
the two groups in the eight dimensions of functioning on
the SF-36, this may have been as a result of the small
numbers involved in the study. However, what was rele-
vant was the greater deterioration in health over the
previous year perceived by the harm minimisation group.
The greater severity of depressive symptoms in this group
may have influenced this perception.
Predictors of psychiatric symptoms were found by Mars-
den et al to be related to severity of drug use, severe
physical health symptoms, previous psychiatric treatment
and conflict in personal relationships.6 In this study, simi-
lar risk factors for psychological morbidity were identified
in clients on the harm minimisation programme. They had
a more severe pattern of drug use, polydrug use, greater
psychological morbidity, previous attendance at psychi-
atric clinics and a greater perception of a deterioration in
their health than clients in treatment on methadone main-
tenance programmes.
From studies there is accumulating evidence of an asso-
ciation of suicidal behaviour and substance misuse with
associated increased risk of attempted and completed
suicide.21-25 Substance misuse is associated with a seven fold
increase in the risk of attempted suicide,24 and a 15 fold
Table 2: Characteristics of attenders on harm minimisation programme
 Numbers living at home with family
 Unemployed
 Severity of drug use
 Use of heroin, cocaine and benzodiazepines 
 Number injecting 
 Number of past treatments for drug use 
 Monthly expenditure on drugs
 Psychological morbidity
 Perceived deterioration of health in the previous year
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increase in the risk of completed suicide.25 The increased
psychological morbidity and suicidal risk in drug users has
implications for the development of services and treatment
programmes, the provision of educative programmes and
in the planning of suicide preventative strategies.
Implications for services
This study highlights differences in perceived quality of
life and psychological morbidity between drug users on a
methadone maintenance programme and those on a harm
minimisation programme. How best psychological/psychi-
atric treatment should be provided remains a source of
debate, be it through the development of a specialist dual
diagnosis service, or through the facilitation of liaison and
networking between substance misuse services, mental
health services primary care, different health, social
services and voluntary sector agencies. 
Hall and Farrell  outlined the need for improvements in
the abilities of staff in addiction services to recognise co-
morbid psychiatric illnesses, and promoted the
development of models of joint care through greater liai-
son between the addiction and mental health services.22
Marsden et al emphasised the importance of a full psychi-
atric assessment to identify clinically significant disorders
and suicidality, to measure the extent of drug use and to
trace the interaction of substance use and the development
of psychiatric disorders.6
Comprehensive care plans need to initially address the
basic physiological needs of drug users, eg. their need for
accommodation, food, medical care, psychiatric care,
employment and financial support, etc. The application of
a ‘keyworker/keyagency’ system in the community would
ensure that drug users are linked up with relevant agencies
who can provide the support necessary to address these
needs. This system would also ensure assertive follow-up
of clients who drop out of treatment.
With regard to the treatment of opiate dependency, there
is much research into alternatives to methadone for the
treatment of opiate withdrawal and dependency and
whether programmes should be focused on abstinence or
harm reduction. Magura et al in a review of published
literature on post discharge outcomes from methadone
detoxification programmes, ‘abstinence orientated’
methadone programs, and methadone maintenance
programmes, found that there was a high reinstatement of
opioid use and subsequent increased death rates once
discontinuing methadone.26 The consensus from the
National Institutes of Health is that methadone mainte-
nance programmes are the most effective treatment for
opiate dependency when coupled with social services, a
comprehensive range of psychological treatments and
vocational rehabilitation.27 
Conclusion
Compared to clients on a methadone maintenance
programme, clients who are on a harm minimisation
programme have a poorer perception of their quality of
life, as indicated by a higher psychological morbidity and
perception of a greater deterioration in health over the
previous year. Although being on methadone maintenance
led to an improvement in one’s perception of ‘change in
health’ over the previous year, psychopathology still
existed for clients on a methadone maintenance
programme. Comprehensive care programmes need to
focus on an individual’s psychological, social and physical
functioning in order to improve progress in treatment and
individuals’ perceptions of their quality of life. 
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